Related Experiment Video

Updated: Aug 14, 2026

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

Pharmaceutical, cellular and genetic therapies for Huntington's disease

Olivia J Handley1, Jenny J Naji, Stephen B Dunnett

  • 1The Brain Repair Group, School of Biosciences, Cardiff University, Cardiff CF10 3US, UK. handleyo@cf.ac.uk

Clinical Science (London, England : 1979)
|December 13, 2005
PubMed

Insights

Huntington's disease (HD) treatments are advancing. Researchers are exploring pharmaceutical, cell, and genetic therapies, offering hope for halting this neurodegenerative disorder.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Huntington's disease (HD) is a fatal neurodegenerative disorder.
  • It results from a polyglutamine expansion in the huntingtin gene.
  • Current treatments for HD are limited and focus on symptom management.

Purpose of the Study:

  • To review recent therapeutic advancements for Huntington's disease.
  • To discuss the translation of these therapies into clinical trials.
  • To provide an outlook on future HD treatment prospects.

Main Methods:

  • Literature review of pharmaceutical, cell-based, and genetic therapies for HD.
  • Analysis of clinical trial progress for emerging HD treatments.
  • Synthesis of current understanding of HD pathology.

Main Results:

  • Multiple therapeutic strategies are under investigation for HD.
  • Several therapies have progressed to clinical trial stages.
  • Advances target underlying pathological mechanisms of HD.

Conclusions:

  • Emerging therapies offer potential for disease modification in HD.
  • Pharmaceutical, cell, and genetic approaches show promise.
  • These advancements provide hope for delaying or halting HD progression.

More Related Videos

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

High Content Screening in Neurodegenerative Diseases13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...